Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465983 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02465983: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT02465983 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465983, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the mesothelin protein. CART19 cells are patients' own T cells that were modified in the laboratory to express a receptor specific to a protein called CD19. The CD19 protein is expressed on white blood B cells. CART19 cells are expected to attack the B cells and impede the antibody response against CART-meso cells. The investigators hypothesize that this combination therapy may prolong the duration of CART-meso cells in the body. Additionally, one dose of cyclophosphamide may enhance engraftment and persistence of CART cells.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL CART-meso-19 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Why NCT02465983 stopped before completion
NCT02465983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT02465983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02465983 about?
NCT02465983 is a clinical study titled "Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer". This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the meso...
What is the current status of trial NCT02465983?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-05. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02465983?
The interventions under investigation include: Cyclophosphamide (DRUG), CART-meso-19 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465983?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02465983's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia